Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) is up more than 40% at 11:53 a.m. EDT after the company released positive phase 3 trial data for the Apollo trial testing its RNAi drug patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. Ionis Pharmaceuticals (NASDAQ: IONS) is down 9.6% because it has a competing drug, inotersen, for the same rare genetic disease.
Ironically, when Ionis released its phase 3 data in May, the same thing happened -- Alnylam went up and Ionis went down -- because Ionis' drug had some side effects and investors were anticipating Alnylam's success.
Image source: Getty Images.
Source: Fool.com
Ionis Pharmaceuticals Inc. Aktie
46,04 €
-0,78 %
Ionis Pharmaceuticals Inc. erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 56 € für Ionis Pharmaceuticals Inc. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 46.04 €.
